Neuroendocrinology News

BOSTON — The majority of people with acromegaly receiving oral octreotide achieve a biochemical response, regardless of their baseline insulin-like growth factor I level, according to data from a post hoc analysis.

BOSTON — Adults with acromegaly previously controlled with standard of care experienced similar disease control with once-monthly injectable octreotide at 24 and 52 weeks, with no serious adverse events, data presented at ENDO 2024 show.

A selective cortisol modulator was linked to lower odds for loss of blood pressure control among adults with Cushing’s syndrome compared with placebo, according to topline results from a phase 3 trial.

The way endocrinologists manage prolactinomas is changing.

More than half of adults with acromegaly receiving a novel once-daily oral medication achieved an insulin-like growth factor-1 level at or below the upper limit of normal, according to topline results from the PATHFNDR-2 trial.

Adults who achieved remission after surgery for Cushing’s disease are more likely to develop autoimmune disease than those with nonfunctioning pituitary adenomas, according to data published in Annals of Internal Medicine.

Hypercortisolism is prevalent among nearly one-quarter of people with difficult-to-control type 2 diabetes enrolled in a prospective phase 4 study, according to an industry press release.

Common data elements are needed to reduce heterogeneity in studies on transsphenoidal pituitary adenoma surgery, according to a systematic review published in Pituitary.

The FDA granted breakthrough therapy designation for an oral non-glucocorticoid medication for the treatment of congenital adrenal hyperplasia, according to an industry press release.

The addition of a radioligand therapy to first-line treatment with long-acting octreotide prolonged PFS for patients with gastroenteropancreatic neuroendocrine tumors, according to the agent’s manufacturer.